Practical Pain Management highlights the 14-3-3η blood test
The 14-3-3η blood test has been highlighted for earlier, more accurate diagnosis of rheumatoid arthritis by Practical Pain Management (PPM), a trusted publication providing evidence-based strategies for the treatment of chronic pain to clinicians and advanced healthcare professionals, written and reviewed by pain experts and leaders in the field.
The article, which will appear in PPM’s Nov/Dec 2022 journal issue, provides a comprehensive profile of the 14-3-3η blood test, explains how it addresses the challenges of early diagnosis, disease monitoring and patient management, and offers practical takeaways for clinicians.
Read the article HERE.
Arthritis-Health.com recognizes the 14-3-3η blood test
The 14-3-3η blood test is now recognized for diagnosing rheumatoid arthritis by Arthritis-Health, a trusted publication of Veritas Health which is produced and blind peer-reviewed by licensed health professionals.
Read the article HERE.
| For a list of 14-3-3η publications visit our publications page. |
The 14-3-3η Blood Test is Available at:
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test which detects the 14-3-3η protein, available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte specific reagents to detect 14-3-3η are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. SPINEstat® expands Augurex’s biomarker-informed diagnostic autoimmune portfolio into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.